EVALUATING EFFICACY AND SAFETY OF SUPRACHOROIDAL TRIAMCINOLONE ACETONIDE FOR PATIENTS WITH RETINAL VEIN OCCLUSION

K CHAUHAN; HK SAIGOL; NI AHMAD; F ALI; S AKHTAR; A RAUF

doi:10.54112/bcsrj.v2023i1.303

Authors

K CHAUHAN Department of Ophthalmology, Sir Ganga Ram Hospital Lahore, Pakistan
HK SAIGOL Department of Ophthalmology, Sir Ganga Ram Hospital Lahore, Pakistan
NI AHMAD Department of Ophthalmology, Sir Ganga Ram Hospital Lahore, Pakistan
F ALI Department of Ophthalmology, Sir Ganga Ram Hospital Lahore, Pakistan
S AKHTAR Department of Ophthalmology, Sir Ganga Ram Hospital Lahore, Pakistan
A RAUF Department of Ophthalmology, Sir Ganga Ram Hospital Lahore, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2023i1.303

Keywords:

Macular, Retinal Vein Occlusion, Suprachoroidal Triamcinolone Acetonide, Macular Edema

Abstract

The prospective study was conducted in the Ophthalmology department, Sir Ganga Ram Hospital, Lahore, from January 2022 to January 2023 to compare the efficacy and safety of intravitreal (IVT) Bevacizumab alone with the suprachoroidal injection of CLS-TA (an injectable form of triamcinolone) along with IVT Bevacizumab in patients with retinal vein occlusion (RVO) induced macular edema in treatment naïve patients. Participants were randomized 1:1 to the IVT Bevacizumab group, and suprachoroidal injection of CLS-TA combined with IVT Bevacizumab group. Participants in both groups were administered drugs and monitored for 30 minutes after the injections. The final evaluation was done after 3 months. Results showed that the Bevacizumab group required 22 re-treatments of the participants for 3 months follow-up, while the combination group required 8 re-treatments (P=0.013). Regarding safety, 1 patient had cataract progression unrelated to the study drug. Combining steroids with vascular endothelial growth factor (VEGF) suppression benefits RVO-induced macular edema. It improves vision, reduces injection frequency, and provides rapid resolution. It is also seen that suprachoroidal delivery of CLS-TA is associated with a reduced risk of increased IOP and cataract progression compared to typical intraocular steroids.

Regarding safety, 1 patient had cataract progression unrelated to the study drug. Combining steroids with vascular endothelial growth factor (VEGF) suppression benefits RVO-induced macular edema. It improves vision, reduces injection frequency, and provides rapid resolution. It is also seen that suprachoroidal delivery of CLS-TA is associated with a reduced risk of increased IOP and cataract progression compared to typical intraocular steroids.

Downloads

Download data is not yet available.

References

Ali, B. M., Azmeh, A. M., and Alhalabi, N. M. (2023). Suprachoroidal triamcinolone acetonide for the treatment of macular edema associated with retinal vein occlusion: a pilot study. BMC ophthalmology 23, 1-13.

Altintas, A. G. K., and Ilhan, C. (2022). Effects of the epiretinal membrane on the outcomes of intravitreal dexamethasone implantation for macular edema secondary to branch retinal vein occlusion. Arquivos Brasileiros de Oftalmologia 86, 13-19.

Belavy, D. L., Tagliaferri, S. D., Buntine, P., Saueressig, T., Samanna, C., McGuckian, T., Miller, C. T., and Owen, P. J. (2022). Reducing low-value imaging for low back pain: systematic review with meta-analysis. Journal of Orthopaedic & Sports Physical Therapy 52, 175-191.

Campochiaro, P. A., and Akhlaq, A. (2021). Sustained suppression of VEGF for treatment of retinal/choroidal vascular diseases. Progress in retinal and eye research 83, 100921.

Georgalas, l., Tservakis, I., Kiskira, E. E., Petrou, P., Papaconstantinou, D., and Kanakis, M. (2019). Efficacy and safety of dexamethasone intravitreal implant in patients with retinal vein occlusion resistant to anti-VEGF therapy: a 12-month prospective study. Cutaneous and Ocular Toxicology 38, 330-337.

James, D. G., Mitkute, D., Porter, G., and Vayalambrone, D. (2019). Visual outcomes following intravitreal ranibizumab for diabetic macular edema in a pro re nata protocol from baseline: a real-world experience. The Asia-Pacific Journal of Ophthalmology 8, 200-205.

Jan, S., Mahsood, Y. J., and Shahnam, T. (2023). Outcomes of Intravitreal Bevacizumab Combined with Suprachoroidal Triamcinolone Acetonide in Central Retinal Vein Occlusion with Macular Edema. Pakistan Journal of Ophthalmology 39.

Jung, J. H., Chae, J. J., and Prausnitz, M. R. (2019). Targeting drug delivery within the suprachoroidal space. Drug discovery today 24, 1654-1659.

Naftali Ben Haim, L., and Moisseiev, E. (2021). Drug delivery via the suprachoroidal space for the treatment of retinal diseases. Pharmaceutics 13, 967.

Nawar, A. E. (2022). Modified microneedle for suprachoroidal injection of triamcinolone acetonide combined with intravitreal injection of ranibizumab in branch retinal vein occlusion patients. Clinical Ophthalmology, 1139-1151.

Poh, S., Tham, Y.-C., Chee, M. L., Dai, W., Majithia, S., Soh, Z. D., Fenwick, E. K., Tao, Y., Thakur, S., and Rim, T. H. (2020). Association between macular thickness profiles and visual function in healthy eyes: The Singapore Epidemiology of Eye Diseases (SEED) Study. Scientific Reports 10, 6142.

Price, K. W., Albini, T. A., and Yeh, S. (2020). Suprachoroidal Injection of Triamcinolone—Review of a Novel Treatment for Macular Edema Caused by Noninfectious Uveitis. US ophthalmic review 13, 76.

Spooner, K., Hong, T., Fraser-Bell, S., and Chang, A. A. (2019). Current outcomes of anti-VEGF therapy in the treatment of macular oedema secondary to branch retinal vein occlusions: a meta-analysis. Ophthalmologica 242, 163-177.

Tayyab, H., Ahmed, C. N., and Sadiq, M. A. A. (2020). Efficacy and safety of suprachoroidal triamcinolone acetonide in cases of resistant diabetic macular edema. Pakistan journal of medical sciences 36, 42.

Zhang, Y., Duan, J., Chang, T., Li, X., Wang, M., and Zhang, M. (2020). Comparative efficacy of intravitreal pharmacotherapy for macular edema secondary to retinal vein occlusion: A protocol for the systematic review and network meta-analysis. Medicine 99.